Dr. Todd Morgan

Yeah, it's awesome. I mean, pretty amazingly early in my career, I think, thanks to some phenomenal mentors that I've had, I had the opportunity to participate in some different AUA and ASCO guideline panels and NCCN. And I, you know, surprised how much I enjoy that process, you know. It is meaningful.

It's like the ultimate, in some ways, of implementation of all the different things that we think about and write about. It's just being part of these multidisciplinary teams, thinking about everybody's different expertise that they bring to the table and learning from them, and then trying to distill

It's like the ultimate, in some ways, of implementation of all the different things that we think about and write about. It's just being part of these multidisciplinary teams, thinking about everybody's different expertise that they bring to the table and learning from them, and then trying to distill

It's like the ultimate, in some ways, of implementation of all the different things that we think about and write about. It's just being part of these multidisciplinary teams, thinking about everybody's different expertise that they bring to the table and learning from them, and then trying to distill

all the science that's produced in some really high-level science and some of the, you know, retrospective work that we all do to, you know, make the best data out of, you know, out of problems where we don't have those RCTs. And so distilling that down to something that's meaningful in the clinic, it's a great process and it's really interesting and fun to be a part of that.

all the science that's produced in some really high-level science and some of the, you know, retrospective work that we all do to, you know, make the best data out of, you know, out of problems where we don't have those RCTs. And so distilling that down to something that's meaningful in the clinic, it's a great process and it's really interesting and fun to be a part of that.

all the science that's produced in some really high-level science and some of the, you know, retrospective work that we all do to, you know, make the best data out of, you know, out of problems where we don't have those RCTs. And so distilling that down to something that's meaningful in the clinic, it's a great process and it's really interesting and fun to be a part of that.

And so when I got the opportunity, you know, AOA reached out and said, hey, we're planning on this project. This guideline, we think the time is right for this. And would you be interested in leaving it? That's, you know, you jump at that opportunity. It was that that was one of those that took me 30 seconds to respond to.

And so when I got the opportunity, you know, AOA reached out and said, hey, we're planning on this project. This guideline, we think the time is right for this. And would you be interested in leaving it? That's, you know, you jump at that opportunity. It was that that was one of those that took me 30 seconds to respond to.

And so when I got the opportunity, you know, AOA reached out and said, hey, we're planning on this project. This guideline, we think the time is right for this. And would you be interested in leaving it? That's, you know, you jump at that opportunity. It was that that was one of those that took me 30 seconds to respond to.

It totally, yep. So there was a prior adjuvant radiation guideline from about 10 years ago. And that was a great guideline. And we can talk more about, you know, where the field was and where it's gone. But this was intended to be totally different, started from scratch.

It totally, yep. So there was a prior adjuvant radiation guideline from about 10 years ago. And that was a great guideline. And we can talk more about, you know, where the field was and where it's gone. But this was intended to be totally different, started from scratch.

It totally, yep. So there was a prior adjuvant radiation guideline from about 10 years ago. And that was a great guideline. And we can talk more about, you know, where the field was and where it's gone. But this was intended to be totally different, started from scratch.

And, you know, when you would ask kind of about the, just the process, it's funny because it's an AUA guideline, but really the urologists make up a minority of the members on this committee, and that's for a good reason. I mean, it's AUA plus Astro and SUO, but, you know, who has expertise in this space? Sure, we do as urologists, but also radiation oncologists.

And, you know, when you would ask kind of about the, just the process, it's funny because it's an AUA guideline, but really the urologists make up a minority of the members on this committee, and that's for a good reason. I mean, it's AUA plus Astro and SUO, but, you know, who has expertise in this space? Sure, we do as urologists, but also radiation oncologists.

And, you know, when you would ask kind of about the, just the process, it's funny because it's an AUA guideline, but really the urologists make up a minority of the members on this committee, and that's for a good reason. I mean, it's AUA plus Astro and SUO, but, you know, who has expertise in this space? Sure, we do as urologists, but also radiation oncologists.

And so my co-chair was Ron Chen, who's just phenomenal, you know, just an amazing radiation oncologist and just such a clear thinker and so knowledgeable. And we had, you know, medical oncologists and patient advocate, nuclear medicine experts. So again, really, really multidisciplinary, and that's fundamental to this space because this is our space, but... is not only our space.

And so my co-chair was Ron Chen, who's just phenomenal, you know, just an amazing radiation oncologist and just such a clear thinker and so knowledgeable. And we had, you know, medical oncologists and patient advocate, nuclear medicine experts. So again, really, really multidisciplinary, and that's fundamental to this space because this is our space, but... is not only our space.

And so my co-chair was Ron Chen, who's just phenomenal, you know, just an amazing radiation oncologist and just such a clear thinker and so knowledgeable. And we had, you know, medical oncologists and patient advocate, nuclear medicine experts. So again, really, really multidisciplinary, and that's fundamental to this space because this is our space, but... is not only our space.

Radiation oncologists have such a huge leadership role in this space, medical oncologists, and all of those collaborations, radiologists are really important. And we really, as we went through the process, we really tried to listen to each other, learn from each other. And I think that that led to a guideline that I'm really proud of.